ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Astellas Dissolves Drug Development Pacts

by Lisa M. Jarvis
March 18, 2013 | APPEARED IN VOLUME 91, ISSUE 11

Astellas Pharma has given back to Cubist Pharmaceuticals the rights to the antibiotic ceftolozane, which is currently being tested in combination with tazobactam in two Phase III studies to treat infections caused by gram-negative bacteria. Astellas, which owned the rights to develop the drug in Asia-Pacific and the Middle East, gets a $25 million up-front fee from Cubist. Astellas has also ended a cancer drug development partnership with Ambit Biosciences. The biotech firm now owns full rights to quizartinib, an FLT3 inhibitor in a Phase IIb study for the treatment of refractory acute myeloid leukemia.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment